

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 003300-831	APPLICATION NO. 09/970,793
	APPLICANT Nils Ove GUSTAVSSON <i>et al.</i>	
	FILING DATE October 5, 2001	GROUP 1615

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
CA	5,981,719		Woiszwilllo <i>et al.</i>	11/1999
	5,849,884		Woiszwilllo <i>et al.</i>	12/1998
	5,776,885		Orsolini <i>et al.</i>	07/1998
	5,753,234		Lee <i>et al.</i>	05/1998
	5,667,808		Johnson <i>et al.</i>	09/1997
	5,654,010		Johnson <i>et al.</i>	08/1997
	5,622,657		Takeda <i>et al.</i>	04/1997
	5,578,709		Woiszwilllo <i>et al.</i>	11/1996
	5,470,582		Supersaxo <i>et al.</i>	11/1995
	5,455,342		Redding, Jr.	10/1995
	5,407,609		Tice <i>et al.</i>	04/1995
	4,713,249		Schröder	12/1987
	4,389,330		Tice <i>et al.</i>	06/1983
	3,881,991		Kurimotor <i>et al.</i>	05/1975
	3,737,337		Schnoring <i>et al.</i>	06/1973
	3,691,090		Kitajima <i>et al.</i>	09/1972

## FOREIGN PATENT DOCUMENTS


Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
CA	WO 99/20253	A1	PCT <del>WPO</del>	04/1999		
	WO 99/00425	A1	PCT <del>WPO</del>	01/1999		
	WO 97/14408	A1	PCT <del>WPO</del>	04/1997		
	WO 96/10042	A1	PCT <del>WPO</del>	04/1996		
	WO 94/12158	A1	PCT <del>WPO</del>	06/1995		
	WO 93/21008	A1	PCI <del>WPO</del>	10/1993		
	EP 0 330 180	B2	EPO	03/1999		
	EP 0 688 429	B1	EPO	02/1998		
	EP 0 540 582	B1	EPO	08/1994		
	EP 0 213 303	A2	EPO	03/1987		
CA	WO 90/13780	A1	PCT <del>WPO</del>	11/1990		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
----------------------	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	003300-831	09/970,793
	APPLICANT	
	Nils Ove GUSTAVSSON <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	October 5, 2001	1615

<input checked="" type="checkbox"/>	Artursson <i>et al.</i> , "Characterization of Polyacryl Starch Microparticles as Carriers for Proteins and Drugs," <i>Journal of Pharmaceutical Sciences</i> , Vol. 73, No. 11, pp. 1507-1513, (1984)
<input type="checkbox"/>	Franssen <i>et al.</i> , "A Novel Preparation Method for Polymeric Microparticles Without the Use of Organic Solvents," <i>International Journal of Pharmaceutics</i> , Vol. 168, pp. 1-7 (1998)
<input type="checkbox"/>	Fu <i>et al.</i> , "Visual Evidence of Acidic Environment Within Degrading Poly(lactic-co-glycolic acid) (PLGA) Microspheres" <i>Pharmaceutical Research</i> , Vol. 17, No. 1, pp. 100-106 (2000)
<input type="checkbox"/>	Laakso <i>et al.</i> , "Biodegradable Microspheres IV: Factors Affecting the Distribution and Degradation of Polyacryl Starch Microparticles," <i>Journal of Pharmaceutical Sciences</i> , Vol. 75, No. 10, pp. 962-967 (1986)
<input type="checkbox"/>	Laakso <i>et al.</i> , "Biodegradable Microspheres X: Some Properties of Polyacryl Starch Microparticles Prepared from Acrylic Acid-Esterified Starch," <i>Journal of Pharmaceutical Sciences</i> , Vol. 76, No. 12, pp. 935-939 (1987)
<input type="checkbox"/>	Schröder, "Crystallized Carbohydrate Spheres as a Slow Release Matrix for Biologically Active Substances," <i>Biomaterials</i> , Vol. 5, pp. 100-104 (1984)
<input type="checkbox"/>	Schröder, "Crystallized Carbohydrate Spheres for Slow Release and Targeting," <i>Enzymology</i> , Vol. 112, No. 9, pp. 116-128 (1985)
<input type="checkbox"/>	Stenekes <i>et al.</i> , "The Preparation of Dextran Microspheres in an All-Aqueous System: Effect of the Formulation Parameters on Particle Characteristics," <i>Pharmaceutical Research</i> , Vol. 15, No. 4 pp. 557-561 (1998)
<input type="checkbox"/>	Stjärnkvist <i>et al.</i> , "Biodegradable Microspheres XIII: Properties of the Crosslinking Chains in Polyacryl Starch Microparticles," <i>Journal of Pharmaceutical Sciences</i> , Vol. 78, No. 1, pp. 52-56 (1989)
<input type="checkbox"/>	Agerse <i>et al.</i> , "Plasma Concentration of hGH and anti-hGH Antibodies After Subcutaneous Administration of hGH for 3 Weeks to Immunosuppressed Pigs," <i>J. Pharmacol Toxicol</i> No. 41 pp. 1-8 (1999)
<input type="checkbox"/>	Johnson <i>et al.</i> , "A Month-Long effect From a Single Injection of Microencapsulated Human Growth Hormone," <i>Nature Medicine</i> , Vol. 2, No. 7 pp. 795-799 (1996)
<input type="checkbox"/>	Putney, "Encapsulation of Proteins for Improved Delivery," <i>Current Opinion in Chemical Biology</i> , Vol. 2, pp. 548-552 (1998)
<input checked="" type="checkbox"/>	"Clean Package Insert," Nutropin Depot (somatropin(rDNA origin) for injectable suspension), Genentech, Inc., 1 DNA Way, South San Francisco, CA 940-4990, pp. 1-6 (December 13, 1999)
<input type="checkbox"/>	
<input type="checkbox"/>	
<input type="checkbox"/>	
<input type="checkbox"/>	
<input type="checkbox"/>	
Examiner Signature	Date Considered
	7/21/04